RxDoctor Payments Data

Judy Okimura, MD

Internal Medicine · Honolulu, HINPI 1356454433

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 24 payments — averaging $54.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$512
  • Amgen$257
  • Lilly USA, LLC$139
  • Corcept Therapeutics$125
  • Eisai Inc.$125
  • Amarin Pharma, Inc.$73
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$1,30099%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 70th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$42,963
Medicare patients
101
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$34,514
OzempicSemaglutide26$26,382
VascepaIcosapent Ethyl30$24,389
MounjaroTirzepatide12$22,344
JardianceEmpagliflozin13$16,786
Atorvastatin Calcium145$4,613
Ezetimibe68$3,885
Rosuvastatin Calcium82$3,713
Losartan Potassium62$1,643
PaxlovidNirmatrelvir/Ritonavir12$1,429
Doxepin Hcl16$1,405
Amlodipine Besylate89$1,250
Irbesartan37$1,164
Olmesartan Medoxomil15$1,162
Pantoprazole Sodium43$1,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$512$26,38226 claims
Lilly USA, LLCMounjaro$139$22,34412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →